Novo Nordisk A/S (LON:0TDD)

Market Cap	309.95B
Revenue (ttm)	32.20B
Net Income (ttm)	11.20B
Shares Out	n/a
EPS (ttm)	2.51
PE Ratio	27.68
Forward PE	n/a
Dividend	0.81 (0.98%)
Ex-Dividend Date	Mar 31, 2025

Volume	230,717
Average Volume	64,005
Open	84.10
Previous Close	83.70
Day's Range	84.10 - 89.23
52-Week Range	98.88 - 149.80
Beta	n/a
RSI	55.65
Earnings Date	Feb 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0TDD

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK